Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Siriraj Hospital

Status and phase: Completed; Phase 4

Conditions: Glaucoma, Neovascular

Treatments: Procedure: Trabeculectomy with mitomycinC; Drug: intravitreal ranibizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT01922154

NK002

Details and patient eligibility

About

To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).

Full description

This is a prospective study of 15 consecutive eyes from 14 patients (One patients had NVG in both eyes at presentation.) with NVG presented at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand between December 2008 and December 2009. Each eye received IVR (0.5 mg/0.05 ml) 1 week before TMC. Trabeculectomy was performed with fornix-based conjunctival flap method.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Consecutive patients with neovascular glaucoma
• Age more than 80 year old
• Provide written informed consent

Exclusion criteria

• Un-cooperated patients

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

intravitreal ranibizumab

Experimental group

Description:

Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.

Treatment:

Drug: intravitreal ranibizumab

Procedure: Trabeculectomy with mitomycinC